therefore , the plasma protein binding of quinidine and the serum level of agp were studied over a 4 day period in each of five cancer patients who were treated with human recombinant-tumour necrosis factor ( hrtnf ) using a dosage schedule of 6-8 x 10 ( +5 ) units/m2 daily for 5 days .
C0017968
agp
C1448177
hrtnf